Purpose We assessed the clinical outcomes of a seton procedure combined with early versus late institution of infliximab (IFX) therapy.
Methods This retrospective study comprised 76 patients who underwent surgery for perianal fistula associated with Crohn disease between January 2014 and November 2017. All patients underwent loose seton drainage combined with IFX therapy. Patients categorized as the early group (EG, 49 patients) received IFX therapy within 30 days of completion of the seton procedure. Patients categorized as the late group (LG, 27 patients) received IFX therapy >30 days after the seton procedure. IFX therapy was administered as induction and maintenance therapy.
Results There were no statistically significant intergroup differences in clinical characteristics of the patients. The mean follow-up was 21.0 ± 11.6 months in the EG and 34.5 ± 18.4 months in the LG (P = 0.001). The mean interval between seton procedure and IFX induction therapy was 12.2 days in the EG and 250.2 days in the LG (P = 0.002). Complete remission was observed in 32 patients (65.3%) in the EG and 17 patients (63.0%) in the LG (P = 0.844). Fistula recurrence was observed in 6 patients (7.9%). All recurrences occurred in a previous perianal fistula tract.
Conclusion Patients showed a good response to a seton procedure combined with IFX therapy regardless of the time of initiation of IFX therapy.
Citations
Citations to this article as recorded by
Management of Anal Fistula with Crohn's Disease Shota Takano, Yasushi Nakamura, Kohei Tamaoka, Takafumi Yoshimoto, Yasue Irei, Yoriyuki Tsuji Journal of the Anus, Rectum and Colon.2025; 9(1): 10. CrossRef
The use of core descriptors from the ENiGMA code study in recent literature: a systematic review Saher‐Zahra Khan, Andrea Arline, Kate M. Williams, Matthew J. Lee, Emily Steinhagen, Sharon L. Stein Colorectal Disease.2024; 26(3): 428. CrossRef
Impact of Seton Use on Clinical, Patient-Reported, and Healthcare Resource Utilization Outcomes in Complex Crohn’s Perianal Fistulas: A Systematic Literature Review Ian White, Chitra Karki, Parnia Geransar, Lilia Leisle, Sophia Junker, Phillip Fleshner Inflammatory Bowel Diseases.2024;[Epub] CrossRef
The Optimal Management of Fistulizing Crohn’s Disease: Evidence beyond Randomized Clinical Trials Panu Wetwittayakhlang, Alex Al Khoury, Gustavo Drügg Hahn, Peter Laszlo Lakatos Journal of Clinical Medicine.2022; 11(11): 3045. CrossRef
The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Anorectal Abscess, Fistula-in-Ano, and Rectovaginal Fistula Wolfgang B. Gaertner, Pamela L. Burgess, Jennifer S. Davids, Amy L. Lightner, Benjamin D. Shogan, Mark Y. Sun, Scott R. Steele, Ian M. Paquette, Daniel L. Feingold Diseases of the Colon & Rectum.2022; 65(8): 964. CrossRef
Management of perianal fistula in inflammatory bowel disease: identification of prognostic factors associated with surgery Sara Gortázar de Las Casas, Mario Alvarez-Gallego, Jose Antonio Gazo Martínez, Natalia González Alcolea, Cristina Barragán Serrano, Aitor Urbieta Jiménez, María Dolores Martín Arranz, Jose Luis Marijuan Martín, Isabel Pascual Migueláñez Langenbeck's Archives of Surgery.2021; 406(4): 1181. CrossRef
Treatment Strategy for Perianal Fistulas in Crohn Disease Patients: The Surgeon’s Point of View Jong Lyul Lee, Yong Sik Yoon, Chang Sik Yu Annals of Coloproctology.2021; 37(1): 5. CrossRef
Multidisciplinary management of perianal Crohn's disease Suha Abushamma, David H. Ballard, Radhika K. Smith, Parakkal Deepak Current Opinion in Gastroenterology.2021; 37(4): 295. CrossRef
Approach to medical therapy in perianal Crohn’s disease Abhinav Vasudevan, David H Bruining, Edward V Loftus, William Faubion, Eric C Ehman, Laura Raffals World Journal of Gastroenterology.2021; 27(25): 3693. CrossRef
Mesenchymal stem cells in perianal Crohn’s disease H. Guadalajara, M. García-Arranz, M. Dolores Herreros, K. Borycka-Kiciak, A. L. Lightner, D. García-Olmo Techniques in Coloproctology.2020; 24(8): 883. CrossRef